Early versus late escalation to extrafine BDP/FF/GB single-inhaler triple therapy in COPD: a real-world subgroup analysis by disease duration since diagnosis.

Unresolved referenced work

Kept as external metadata until matched

The 2023 GOLD Report: Updated Guidelines for Inhaled Pharmacological Therapy in Patients with Stable COPD, Pulm

2023

Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports

10.1007/s12325-020-01289-y · 2020

BDP/FF/GB single-inhaler triple therapy in COPD: real-world effectiveness, safety, and adherence in a pooled analysis of 5,000 patients

10.1016/j.rmed.2026.108743 · 2026

TRICOP – A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD

10.1016/j.rmed.2021.106398 · 2021

Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany – The TriOptimize Study

10.2147/copd.s382405 · 2022

Extrafine single inhaler triple therapy effect on health status, lung function and adherence in COPD patients: A Panhellenic prospective non-interventional study – The TRIBUNE study

10.1016/j.rmed.2023.107219 · 2023

Evolving to a single inhaler extrafine LABA/LAMA/ICS – Inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE)

10.1016/j.rmed.2023.107368 · 2023